SCHEMBL11907804

SCHEMBL11907804

CCCNC(=O)c1ccc(F)c(-c2ccc(N)c(C(=O)O)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
ASIC3 Q9UHC3 1/20 0.42
MCHR1 Q99705 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA2 P47869 1/20 0.39
POLB P06746 1/20 0.39
PIM1 P11309 3/20 0.38
PIM3 Q86V86 3/20 0.38
PIM2 Q9P1W9 3/20 0.38
TERT O14746 2/20 0.38
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38
KMT2A Q03164 1/20 0.38
PDK2 Q15119 1/20 0.38
MAPK14 Q16539 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11908359 0.91 PDE2A (0.40) ASIC3MCHR1PIM1PIM3PIM2
SCHEMBL11906672 0.85 PLAU (0.41) PIM1PIM3PIM2
SCHEMBL4436068 0.82 PIM2 (0.52) PIM1PIM3PIM2PDK2MAPK14
SCHEMBL11907368 0.80 ATR (0.50) ALDH1A1PIM1PIM3PIM2
SCHEMBL11906777 0.79 LMNA (0.47) ALDH1A1KDM4EGAAHPGDL3MBTL1
SCHEMBL11907179 0.78 ALOX5AP (0.41) PIM1PIM3PIM2
SCHEMBL11984622 0.77 PIM2 (0.60) PIM1PIM3PIM2
SCHEMBL11906876 0.76 CTSA (0.40) PIM1PIM3PIM2
SCHEMBL1711905 0.76 PIM1 (0.53) PIM1PIM3PIM2KMT2A
SCHEMBL11908142 0.75 DHODH (0.49) ALDH1A1KDM4EHPGDL3MBTL1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 ALDH1A1 2176/4885KDM4E 946/4885GAA 1434/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 ALDH1A1 2176/4885KDM4E 946/4885GAA 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.